Abstract: Inflammatory bowel disease (IBD) is a kind of chronic, relapsing inflammatory disease of the gastrointestinal tract with unknown etiology. Its treatment is still dominated by traditional medicine. Due to the obvious adverse reactions of these traditional drugs, a variety of biological agents have been derived in recent years, such as anti-tumor necrosis factor(TNF) biological agents, integrin antagonists. As a humanized anti- α4β7 integrin monoclonal antibody, vedolizumab can selectively block trafficking of memory T cells to inflamed intestinal tissues by inhibiting the interaction of α4β7 integrin with mucosal address cell adhesion molecule-1, reducing intestinal inflammation. Therefore, it is mainly used in IBD patients who are failed to respond to the anti-TNF biological agents. This review will discuss the mechanism, clinical efficacy and safety of vedolizumab in the treatment of IBD.

Key words: inflammatory bowel disease, Vedolizumab, integrin, mucosal addressin cell adhesion molecule-1